LECT2 and Hepatic fibrosis: The shortcomings of bevacizumab and rVEGF in regulating different microvessels in the treatment of liver fibrosis are made up for by AAV9-LECT2 shRNA, the combination of varying angiogenesis modulators further improves the therapeutic effect on liver fibrosis, and the side effects of bevacizumab combination therapy are relatively less (58).